-transparent.png){kind=logo}
Since its emergence onto the gene therapy scene nearly 25 years ago, the replication-defective Herpes Simplex Virus Type-1 (HSV-1) amplicon has gained significance as a versatile gene transfer platform due to its extensive transgene capacity, widespread cellular tropism, minimal immunogenicity, and its amenability to genetic manipulation. Herein, we detail the recent advances made with respect to the design of the HSV amplicon, its numerous in vitro and in vivo applications, and the current impediments this virus-based gene transfer platform faces as it navigates a challenging path towards future clinical testing.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Suresh de Silva, and
William J Bowers
January 1994,
Methods in cell biology,
Suresh de Silva, and
William J Bowers
June 2006,
Current gene therapy,
Suresh de Silva, and
William J Bowers
January 2003,
Methods in molecular medicine,
Suresh de Silva, and
William J Bowers
September 2005,
BioTechniques,
Suresh de Silva, and
William J Bowers
January 2011,
Methods in molecular biology (Clifton, N.J.),
Suresh de Silva, and
William J Bowers
January 2014,
Methods in molecular biology (Clifton, N.J.),
Suresh de Silva, and
William J Bowers
January 1999,
Blood,
Suresh de Silva, and
William J Bowers
October 1996,
Human gene therapy,
Suresh de Silva, and
William J Bowers
April 1995,
Human gene therapy,
Suresh de Silva, and
William J Bowers
January 2020,
Methods in molecular biology (Clifton, N.J.),
